Behavioral characterization of a mutant mouse strain lacking d-amino acid oxidase activity

[1]  J. Roder,et al.  Mutant mice with reduced NMDA-NR1 glycine affinity or lack of d-amino acid oxidase function exhibit altered anxiety-like behaviors , 2009, Pharmacology Biochemistry and Behavior.

[2]  J. Roder,et al.  Genetic inactivation of D-amino acid oxidase enhances extinction and reversal learning in mice. , 2008, Learning & memory (Cold Spring Harbor, N.Y.).

[3]  L. Cavarec,et al.  In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties , 2008, European Neuropsychopharmacology.

[4]  D. Javitt,et al.  The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. , 2007, The American journal of psychiatry.

[5]  C. Chiu,et al.  Behavioral and biochemical characterization of a mutant mouse strain lacking d-amino acid oxidase activity and its implications for schizophrenia , 2006, Molecular and Cellular Neuroscience.

[6]  J. Mothet,et al.  d-Serine signalling in the brain: friend and foe , 2006, Trends in Neurosciences.

[7]  F. McMahon,et al.  G72/G30 in Schizophrenia and Bipolar Disorder: Review and Meta-analysis , 2006, Biological Psychiatry.

[8]  R. Sullivan,et al.  Immunocytochemical analysis of D‐serine distribution in the mammalian brain reveals novel anatomical compartmentalizations in glia and neurons , 2006, Glia.

[9]  M. Maekawa,et al.  Spatial learning and long-term potentiation of mutant mice lacking d-amino-acid oxidase , 2005, Neuroscience Research.

[10]  D. Goff,et al.  A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients , 2005, Psychopharmacology.

[11]  Daniel C. Javitt,et al.  D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia , 2005, Biological Psychiatry.

[12]  A. Hashimoto,et al.  Mice lacking d-amino acid oxidase activity display marked attenuation of stereotypy and ataxia induced by MK-801 , 2005, Brain Research.

[13]  M. E. Ballard,et al.  Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia , 2004, Psychopharmacology.

[14]  Nicholas Lange,et al.  Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia , 2004, Biological Psychiatry.

[15]  S. Cichon,et al.  Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder , 2004, Molecular Psychiatry.

[16]  D. Javitt,et al.  High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia , 2004, Biological Psychiatry.

[17]  P. Sham,et al.  Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Morikawa,et al.  Determination of free D-aspartic acid, D-serine and D-alanine in the brain of mutant mice lacking D-amino acid oxidase activity. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[19]  R. Konno,et al.  Exaggerated responses to chronic nociceptive stimuli and enhancement of N-methyl-d-aspartate receptor-mediated synaptic transmission in mutant mice lacking d-amino-acid oxidase , 2001, Neuroscience Letters.

[20]  M. Geyer,et al.  Effects of strain and serotonergic agents on prepulse inhibition and habituation in mice , 2000, Neuropharmacology.

[21]  S H Snyder,et al.  Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  C. Parsons,et al.  Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. , 1998, Pharmacological reviews.

[23]  S. Snyder,et al.  d-Serine as a Neuromodulator: Regional and Developmental Localizations in Rat Brain Glia Resemble NMDA Receptors , 1997, The Journal of Neuroscience.

[24]  J. Olney,et al.  NMDA Antagonists as Neurotherapeutic Drugs, Psychotogens, Neurotoxins, and Research Tools for Studying Schizophrenia , 1995, Neuropsychopharmacology.

[25]  T. Nishikawa,et al.  Free d-serine, d-aspartate and d-alanine in central nervous system and serum in mutant mice lacking d-amino acid oxidase , 1993, Neuroscience Letters.

[26]  T. Nishikawa,et al.  Endogenous d‐Serine in Rat Brain: N‐Methyl‐d‐Aspartate Receptor‐Related Distribution and Aging , 1993, Journal of neurochemistry.

[27]  R. Konno,et al.  A single-base-pair substitution abolishes D-amino-acid oxidase activity in the mouse. , 1992, Biochimica et biophysica acta.

[28]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[29]  R. Konno,et al.  Mouse mutant deficient in D-amino acid oxidase activity. , 1983, Genetics.

[30]  Masafumi Ogawa,et al.  Pharmacological treatments of cerebellar ataxia , 2008, The Cerebellum.